返回 A A A Font Size Receive E-mail Alerts Press Releases

First Case of Firehawk® in Tibet Completed

[2017-10-10] 

Lhasa, China – On September 6, the first PCI case of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") in Tibet Autonomous Region was successfully completed in Chinese Armed Police Force of Tibet Autonomous Region Hospital. Firehawk® is a stent in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®").
 
The surgery was performed by Professor Chengxi Yin of Beijing Anzhen Hospital of Capital Medical University. The female patient, 54, had been suffering from leg edema, chest distress, and chest pain for a long period. On September 6, after coronary arteriography diagnosis, she was implanted two Firehawk® stents and achieved immediate remission of symptoms. As the only coronary stent approved for use in Chinese Armed Police Force of Tibet Autonomous Region Hospital, Firehawk® won high recognition from physicians and patients with its outstanding performance in PCI cases.
 
Tibetans are more likely to develop atherosclerosis of coronary artery due to their living conditions and diet habits. They live in the Tibet Plateau with 4,000 to 5,000 meters in altitude, and under such cold, low oxygen and low pressure living condition, the red blood cell would increase, leading to blood viscosity, slow blood flow and even microcirculation disturbance. Besides, they largely rely on food high in salt, fat and calorie, but lacking of vitamin and microelement, which would also increase the risk of atherosclerosis of coronary artery.
 
The coronary accessory of MicroPort® was first used in Chinese Armed Police Force of Tibet Autonomous Region Hospital for coronary angiogram in April 2017, and the first PCI case of Firehawk® marks the its coverage of all the provinces in the Chinese mainland. As the leading coronary stent provider in China, MicroPort® is committed to offering high-quality and more affordable solutions for patients with coronary heart disease and will continue to organize free clinic, donation activities, training courses, and surgery demonstrations to improve the medical treatment in minority areas to save more patients or improve their life quality.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Hosts Supply Chain Innovation Summit
[Next]:The First Case of Firehawk® in Kazakhstan Completed